In light of this, we found Smyd2 knockdown or heterozygous knockout mice ameliorates endothelial inflammation (iNOS, VCAM-1 and COX-2) upon Ang II infusion in vivo, which revealed that targeting Smyd2 possibly unveiled a novel therapeutic candidate of age-related endothelial inflammation. Here, SMYD2 is linked to age.